Delenex Therapeutics makes two senior appointments

Eric de La Fortelle joins as ceo and Jakob Schlapbach as cfo

Swiss biotechnology firm Delenex Therapeutics has appointed Eric de La Fortelle as chief executive and Jakob Schlapbach as chief finance officer.

La Fortelle was previously global head of external research and technologies at F. Hoffmann-La Roche and more recently global head, emerging technologies. His scientific work contributed to the field of protein structure determination and he was the initial lead author of the SHARP software, which contributed to the resolution of more than 1,000 protein structures by X-ray crystallography.

Schlapbach joined Delenex last December 2010 as cfo. He brings more than 30 years of banking and industrial financing experience to the company. He was cfo of Cytos Biotechnology for more than 10 years until mid-2010 and held the same position at Ascom group between 1994 and 2000.


Thomas Hecht, chairman of Delenex, said: ‘We are pleased and proud to have attracted two managers of such a high calibre to Delenex.’

Delenex Therapeutics AG is developing therapeutic PENTRA antibody fragments targeting serious medical diseases with high unmet need.

Delenex is a spin-off from ESBATech before its acquisition by Alcon in September 2009 and operates out of laboratories and offices in Zürich-Schlieren.

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility

The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Subscribe now